These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2009-011099-31 A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 ... 2011-01-14 due-trials
Not reported Terminated 2010-021963-34 A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus Rib... 2011-02-04 due-trials
Not reported Terminated 2011-000091-33 A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus, Genotype 1 2012-01-20 due-trials
Completed, but no date 2013-000164-28 A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe bad-data
Not reported 2015-003277-15 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis 2018-04-04 due-trials
Ongoing 2017-002454-36 A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma not-yet-due